Bone Therapeutics has treated 12 patients in the ALLOB® Phase IIA spinal fusion trial, and reports no safety concerns. One patient cohort of four patients remains to be treated.
Bone Therapeutics seeks to support spinal fusion rates by including the ALLOB allogeneic bone-forming cell product in the procedure. This pilot Phase IIA study will enroll 16 patients with symptomatic degenerative lumbar disc disease who require interbody fusion surgery.
The trial is running in 8 centers in Belgium. Bone Therapeutics expects to update in 1H16 on the efficacy of ALLOB in the 1st cohort patients in this trial, after 12-month follow-up. Study completion is estimated for early 2Q19.
Bone Therapeutics has treated 12 patients in the ALLOB® Phase IIA spinal fusion trial, and reports no safety concerns. One patient cohort of four patients remains to be treated.
Bone Therapeutics seeks to support spinal fusion rates by including the ALLOB allogeneic bone-forming cell product in the procedure. This pilot Phase IIA study will...
Bone Therapeutics has treated 12 patients in the ALLOB® Phase IIA spinal fusion trial, and reports no safety concerns. One patient cohort of four patients remains to be treated.
Bone Therapeutics seeks to support spinal fusion rates by including the ALLOB allogeneic bone-forming cell product in the procedure. This pilot Phase IIA study will enroll 16 patients with symptomatic degenerative lumbar disc disease who require interbody fusion surgery.
The trial is running in 8 centers in Belgium. Bone Therapeutics expects to update in 1H16 on the efficacy of ALLOB in the 1st cohort patients in this trial, after 12-month follow-up. Study completion is estimated for early 2Q19.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
